Country: Austria
Language: English
Source: HMA (Heads of Medicines Agencies)
buprenorphine hydrochloride 0.32 mg/ml
Richter Pharma AG
QN02AE01
Solution for injection
buprenorphine
Cats, Dogs
2011-08-16
BUPAQ 0.3 MG/ML SOLUTION FOR INJECTION FOR DOGS AND CATS S PC_LABELLING_PIL_PROPOSAL FOR DCP 17 AUGUST 2011 1 _[Version 7.3, 04/2010] _ _ _ _ _ _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, CZ, DE, ES, FR, HU, IE, IT, PT, SK, UK: Bupaq Multidose 0.3 mg/ml Solution for injection for dogs and cats FI: Bupaq vet Multidose 0.3 mg/ml Solution for injection SE: Bupaq vet 0.3 mg/ml Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Buprenorphine (as hydrochloride) 0.3 mg EXCIPIENT: Chlorocresol 1.35 mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Solution for injection Clear, colourless to almost colourless solution 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES DOG Post-operative analgesia. Potentiation of the sedative effects of centrally-acting agents. CAT Post-operative analgesia. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not administer by the intrathecal or peridural route. Do not use pre-operatively for Caesarian section (see section 4.7). 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE 3 SPECIAL PRECAUTIONS FOR USE IN ANIMALS Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cau Read the complete document